Benzinga | Jan 10, 2022 07:57AM EST

SVB Leerink Maintains Outperform on Beam Therapeutics, Raises Price Target to $121

SVB Leerink analyst Rick Bienkowski maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and raises the price target from $116 to $121.